O	0	5	Phase
O	6	7	3
O	8	13	study
O	14	23	comparing
O	24	27	the
O	28	31	use
O	32	34	of
B-intervention	35	44	docetaxel
I-intervention	45	47	on
I-intervention	48	50	an
I-intervention	51	56	every
I-intervention	56	57	-
I-intervention	57	58	3
I-intervention	58	59	-
I-intervention	59	63	week
O	64	70	versus
B-control	71	77	weekly
I-control	78	86	schedule
O	87	89	in
O	90	93	the
O	94	103	treatment
O	104	106	of
O	107	117	metastatic
O	118	124	breast
O	125	131	cancer
O	131	132	.

O	133	141	Previous
O	142	149	studies
O	150	154	have
O	155	164	evaluated
O	165	166	3
O	166	167	-
O	167	171	week
O	172	175	and
O	176	182	weekly
O	183	192	docetaxel
O	193	202	schedules
O	203	205	in
O	206	214	patients
O	215	219	with
O	220	230	metastatic
O	231	237	breast
O	238	244	cancer
O	245	246	(
O	246	249	MBC
O	249	250	)
O	250	251	.

O	252	255	The
O	256	263	varying
O	264	272	efficacy
O	273	280	results
O	281	284	and
O	285	293	toxicity
O	294	302	profiles
O	303	308	noted
O	309	311	in
O	312	317	these
O	318	325	earlier
O	326	333	studies
O	334	337	led
O	338	340	to
O	341	342	a
O	343	353	comparison
O	354	356	of
O	357	360	the
O	361	370	schedules
O	371	373	to
O	374	383	determine
O	384	389	which
O	390	393	was
O	394	399	safer
O	400	403	and
O	404	408	more
O	409	420	efficacious
O	420	421	.

O	422	423	A
O	424	429	phase
O	430	431	3
O	432	440	clinical
O	441	446	trial
O	447	450	was
O	451	460	conducted
O	461	463	in
B-eligibility	464	472	patients
I-eligibility	473	477	with
I-eligibility	478	481	MBC
O	482	485	who
O	486	490	were
O	491	498	treated
O	499	503	with
O	504	513	docetaxel
O	514	520	either
O	521	526	every
O	527	528	3
O	529	534	weeks
O	535	537	or
O	538	542	once
O	543	549	weekly
O	550	552	to
O	553	562	determine
O	563	566	and
O	567	574	compare
O	575	583	response
O	584	588	rate
O	589	592	and
O	593	601	duration
O	601	602	,
O	603	607	time
O	608	610	to
O	611	618	disease
O	619	630	progression
O	630	631	,
O	632	643	progression
O	643	644	-
O	644	648	free
O	649	657	survival
O	658	659	(
O	659	662	PFS
O	662	663	)
O	663	664	,
O	665	672	overall
O	673	681	survival
O	682	683	(
O	683	685	OS
O	685	686	)
O	686	687	,
O	688	691	and
O	692	700	toxicity
O	700	701	.

O	702	710	Patients
O	711	715	were
O	716	726	randomized
O	727	729	to
O	730	737	receive
O	738	747	docetaxel
O	748	750	at
O	751	752	a
O	753	761	starting
O	762	766	dose
O	767	769	of
O	770	776	either
O	777	779	75
O	780	782	mg
O	782	783	/
O	783	784	m
O	784	785	(
O	785	786	2
O	786	787	)
O	788	793	every
O	794	795	3
O	796	801	weeks
O	802	804	or
O	805	807	35
O	808	810	mg
O	810	811	/
O	811	812	m
O	812	813	(
O	813	814	2
O	814	815	)
O	816	822	weekly
O	823	826	for
O	827	828	3
O	829	840	consecutive
O	841	846	weeks
O	847	855	followed
O	856	858	by
O	859	860	1
O	861	865	week
O	866	868	of
O	869	873	rest
O	873	874	.

O	875	876	A
O	877	882	total
O	883	885	of
B-total-participants	886	889	118
O	890	898	patients
O	899	908	underwent
O	909	917	efficacy
O	918	926	analysis
O	926	927	;
B-intervention-participants	928	930	59
O	931	939	patients
O	940	944	were
O	945	955	randomized
O	956	958	to
O	959	962	the
O	963	968	every
O	968	969	-
O	969	970	3
O	970	971	-
O	971	975	week
O	976	985	treatment
O	986	989	arm
O	990	993	and
B-control-participants	994	996	59
O	997	999	to
O	1000	1003	the
O	1004	1010	weekly
O	1011	1014	arm
O	1014	1015	.

O	1016	1019	The
B-outcome	1020	1028	response
I-outcome	1029	1033	rate
O	1034	1037	was
B-iv-bin-percent	1038	1040	35
I-iv-bin-percent	1040	1041	.
I-iv-bin-percent	1041	1042	6
I-iv-bin-percent	1042	1043	%
O	1044	1045	(
O	1045	1047	95
O	1047	1048	%
O	1049	1059	confidence
O	1060	1068	interval
O	1069	1070	[
O	1070	1072	95
O	1072	1073	%
O	1074	1076	CI
O	1076	1077	]
O	1077	1078	,
O	1079	1081	23
O	1081	1082	.
O	1082	1083	6
O	1083	1084	-
O	1084	1086	49
O	1086	1087	.
O	1087	1088	1
O	1088	1089	%
O	1089	1090	)
O	1091	1094	for
O	1095	1098	the
O	1099	1104	every
O	1104	1105	-
O	1105	1106	3
O	1106	1107	-
O	1107	1111	week
O	1112	1115	arm
O	1116	1122	versus
B-cv-bin-percent	1123	1125	20
I-cv-bin-percent	1125	1126	.
I-cv-bin-percent	1126	1127	3
I-cv-bin-percent	1127	1128	%
O	1129	1130	(
O	1130	1132	95
O	1132	1133	%
O	1134	1136	CI
O	1136	1137	,
O	1138	1140	11
O	1140	1141	.
O	1141	1142	0
O	1142	1143	-
O	1143	1145	32
O	1145	1146	.
O	1146	1147	8
O	1147	1148	%
O	1148	1149	)
O	1150	1153	for
O	1154	1157	the
O	1158	1164	weekly
O	1165	1168	arm
O	1168	1169	.

O	1170	1175	There
O	1176	1179	was
O	1180	1182	no
O	1183	1194	statistical
O	1195	1205	difference
O	1206	1213	between
O	1214	1217	the
O	1218	1223	every
O	1224	1225	3
O	1225	1226	-
O	1226	1230	week
O	1231	1234	and
O	1235	1238	the
O	1239	1245	weekly
O	1246	1255	treatment
O	1256	1260	arms
O	1261	1265	with
O	1266	1272	regard
O	1273	1275	to
B-outcome	1276	1282	median
I-outcome	1283	1286	PFS
O	1287	1288	(
B-iv-cont-median	1288	1289	5
I-iv-cont-median	1289	1290	.
I-iv-cont-median	1290	1291	7
I-iv-cont-median	1292	1298	months
O	1299	1301	vs
B-cv-cont-median	1302	1303	5
I-cv-cont-median	1303	1304	.
I-cv-cont-median	1304	1305	5
I-cv-cont-median	1306	1312	months
O	1312	1313	;
O	1314	1315	P
O	1315	1316	=
O	1317	1318	.
O	1318	1320	46
O	1320	1321	)
O	1322	1324	or
B-outcome	1325	1327	OS
O	1328	1329	(
B-iv-cont-median	1329	1331	18
I-iv-cont-median	1331	1332	.
I-iv-cont-median	1332	1333	3
I-iv-cont-median	1334	1340	months
O	1341	1343	vs
B-cv-cont-median	1344	1346	18
I-cv-cont-median	1346	1347	.
I-cv-cont-median	1347	1348	6
I-cv-cont-median	1349	1355	months
O	1355	1356	,
O	1357	1369	respectively
O	1369	1370	;
O	1371	1372	P
O	1372	1373	=
O	1374	1375	.
O	1375	1377	34
O	1377	1378	)
O	1378	1379	.

O	1380	1385	There
O	1386	1389	was
O	1390	1391	a
O	1392	1398	higher
B-outcome	1399	1406	overall
I-outcome	1407	1415	toxicity
I-outcome	1416	1420	rate
O	1421	1422	(
O	1422	1428	grades
O	1429	1430	3
O	1431	1434	and
O	1435	1436	4
O	1436	1437	,
O	1438	1447	according
O	1448	1450	to
O	1451	1454	the
O	1455	1463	National
O	1464	1470	Cancer
O	1471	1480	Institute
O	1481	1487	Common
O	1488	1496	Toxicity
O	1497	1505	Criteria
O	1506	1507	[
O	1507	1514	version
O	1515	1516	2
O	1516	1517	.
O	1517	1518	0
O	1518	1519	]
O	1519	1520	)
O	1521	1523	in
O	1524	1527	the
O	1528	1533	every
O	1533	1534	-
O	1534	1535	3
O	1535	1536	-
O	1536	1540	week
O	1541	1550	treatment
O	1551	1554	arm
O	1555	1561	versus
O	1562	1565	the
O	1566	1572	weekly
O	1573	1582	treatment
O	1583	1586	arm
O	1587	1588	(
B-iv-bin-percent	1588	1590	88
I-iv-bin-percent	1590	1591	.
I-iv-bin-percent	1591	1592	1
I-iv-bin-percent	1592	1593	%
O	1594	1596	vs
B-cv-bin-percent	1597	1599	55
I-cv-bin-percent	1599	1600	.
I-cv-bin-percent	1600	1601	9
I-cv-bin-percent	1601	1602	%
O	1602	1603	,
O	1604	1616	respectively
O	1616	1617	;
O	1618	1619	P
O	1619	1620	=
O	1621	1622	.
O	1622	1626	0001
O	1626	1627	)
O	1627	1628	.

O	1629	1637	Compared
O	1638	1642	with
O	1643	1651	patients
O	1652	1655	who
O	1656	1664	received
O	1665	1671	weekly
O	1672	1681	docetaxel
O	1681	1682	,
O	1683	1688	those
O	1689	1692	who
O	1693	1701	received
O	1702	1711	docetaxel
O	1712	1717	every
O	1718	1719	3
O	1720	1725	weeks
O	1726	1729	had
O	1730	1731	a
O	1732	1738	higher
O	1739	1747	response
O	1748	1752	rate
O	1753	1756	but
O	1757	1768	experienced
O	1769	1776	similar
O	1777	1780	PFS
O	1781	1784	and
O	1785	1787	OS
O	1788	1791	and
O	1792	1793	a
O	1794	1798	more
O	1799	1809	pronounced
O	1810	1818	toxicity
O	1818	1819	.
